



## Risk of Thromboembolism in Nonvalvular Atrial Fibrillation

Merdad Hassan<sup>1\*</sup>, Abdulazizi I Alroshodi<sup>1</sup>, Ghazi T AlMutairi<sup>2</sup>, Abdullah A Alfheid<sup>2</sup>, Mashari Alzahrani<sup>3</sup>, Khaled A Alqarni<sup>3</sup>, Naif Saad Alghasab<sup>4</sup>, Alzead Ahmed A<sup>4</sup>, Mashary A Attamimi<sup>5</sup>, Fahad Alshehri<sup>5</sup>

<sup>1</sup>Department of Internal Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

<sup>2</sup>Department of Internal Medicine, King Faisal Medical City for Southern Region, Riyadh, Saudi Arabia

<sup>3</sup>Department of Medicine, Qassim University, Buraydah, Saudi Arabia

<sup>4</sup>Department of Medicine, Security Force Hospital, Riyadh, Saudi Arabia

<sup>5</sup>Department of Cardiology, Hail University, Hail, Saudi Arabia

\*Corresponding e-mail: [hassan64.md@gmail.com](mailto:hassan64.md@gmail.com)

**Received:** 16-Jun-2020, Manuscript No. IJMRHS-20-13611; **Editor assigned:** 19-Jun-2020, PreQC No. IJMRHS-20-13611 (PQ); **Reviewed:** 03-Jul-2020, QC No. IJMRHS-20-13611 (Q); **Revised:** 09-Sep-2022, QI No. IJMRHS-20-13611, Manuscript No. IJMRHS-20-13611 (R); **Published:** 07-Oct-2022

### ABSTRACT

**Objectives:** Atrial fibrillation is associated with atrial thrombus formation and peripheral embolization, which leads to ischemic stroke or systemic thromboembolism. The CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc scores are tool for estimating risk of stroke in Nonvalvular Atrial Fibrillation (NVAF) patients. data on scores variables, Body Mass Index (BMI) and Chronic Kidney Disease (CKD) with reduced glomerular filtration rate on their implication in identify Thromboembolic Events (TE) in Saudi population with NVAF are quite limited. So, we examined CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-vasc scores variables, BMI and estimated Glomerular Filtration Rate (eGFR) of CKD in identify thromboembolic events and if would be give incremental information in predicting thromboembolic event in NVAF Saudi patients.

**Methods:** The study consisted of 541 patients with AF seen in our institution from 2008 to 2013 were identified in database, 175 were NVAF. Thromboembolic end points were defined as ischemic stroke and systemic embolism. During follow-up period of 730 days, CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc scores components, BMI also CKD and association with TEs end points identified by Cox regression analysis.

**Results:** Of 175 patients with NVAF, 26 (14.9%) patients were identified to have TEs. Majority of them had stroke. Age ( $\geq 75$  years) and Peripheral vascular disease were significant factors for TEs. Thromboembolic risk in patients had previous stroke or TIA was 38.5% ( $P$  value=0.000). Events rate of thromboembolism increased when CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-VASc score increased. No statistically significant associations were observed with BMI and TEs. Study has shown Despite only 35% of study population is suffering from CKD however level of estimated glomerular filtration rate was significant factor for TEs in patients with nonvalvular atrial fibrillation.

**Conclusion:** Study demonstrated CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc, CKD are predictor of TEs and should be included in risk stratification schemes among NVAF Saudi patients. And obese patient was not. So, keeping this association in consideration during thromboembolism risk assessment is recommended.

**Keywords:** Atrial fibrillation, Risk of thromboembolism, Body mass index, Chronic kidney disease

## INTRODUCTION

Embolization of atrial thrombi can occur with paroxysmal, persistent or permanent Atrial Fibrillation (AF). The most commonly occurring and often the most severe thrombi are those that occur in the brain during the clinical course of AF and manifest as an ischemic stroke. Other systemic and pulmonary thromboembolism may also occur, but are less commonly recognized. To prevent ischemic strokes and systemic embolization, chronic antithrombotic therapy with either oral anticoagulation or antiplatelet therapy is often prescribed. Antithrombotic therapies associated with increased risk of bleeding. In treating AF patients, physicians must consider both the benefits and risks. AF in the presence of mechanical prosthetic heart valve or moderate to severe rheumatic mitral valve disease are defined as Valvular AF where the use of Vitamin K Antagonists (VKA) for the prevention of thromboembolic events is the only established option. While the term Non-Valvular Atrial Fibrillation (NVAf) has become popular with the development of non-VKA, Direct Oral Anti-Coagulants (DOAC). Numerous studies have evaluated risk factors for embolization in nonvalvular atrial fibrillation AF and multivariate models have been constructed to stratify ischemic strokes and systemic embolization risk in AF. The CHADS<sub>2</sub> (congestive heart failure, hypertension, age  $\geq$  75 years old, diabetes, prior TIA or stroke) score is one of the models used for estimating the risk of ischemic strokes and systemic embolization in patients with NVAf. Historically, the CHADS<sub>2</sub> risk score is the most popular and has been best validated in different patient populations [1-3].

To complement the CHADS<sub>2</sub> score, additional stroke risk modifier risk factors were included and the CHA<sub>2</sub>DS<sub>2</sub>-vasc score was developed. These additional risk factors include age 65-74, female gender and vascular disease in an effort to provide a more refined risk of ischemic strokes and systemic embolization and provides significant information in AF patients with a CHADS<sub>2</sub> score of 0-1. Even in patients categorized as 'low risk' using a CHADS<sub>2</sub> score=0, the CHA<sub>2</sub>DS<sub>2</sub>-vasc score significantly improved the predictive value of the CHADS<sub>2</sub> score alone and a CHA<sub>2</sub>DS<sub>2</sub>-vasc score=0 could clearly identify 'truly low risk' subjects. The CHA<sub>2</sub>DS<sub>2</sub>-vasc score has been used in the new European Society of Cardiology guidelines for the management of atrial fibrillation [4].

Chronic Kidney Disease (CKD) is an independent risk factor for cardiovascular disease outcomes, such as hypertension, heart failure and myocardial infarction. Also, CKD demonstrated as independent risk of stroke in patients with AF without anticoagulation therapy. The Danish national registry revealed that the risk of stroke or systemic embolism was higher in CKD patients with NVAf compared with those who did not have renal disease and even higher in those requiring dialysis. Reduced creatinine clearance was a strong independent predictor for stroke in the ROCKETAF and ATRIA study cohorts and use a CKD as part of the risk stratification scheme in NVAf patients [5-8].

Obesity is a modifiable risk factor for so many cardiovascular diseases, especially a attributable risk factor for AF. Obesity and metabolic syndrome are not considered risk factors to help prevent stroke and other thromboembolic events in atrial fibrillation patients. However, there is some evidence to suggest they should, in a study examining the risk of left atrial thrombus in patients with AF, subjects with a Body Mass Index (BMI)  $\geq$  27 had a markedly increased risk of left atrial appendage thrombus [9]. So our current retrospective study, examined CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-vasc scores variables risks of Thromboembolic Events (TEs) in Saudi patients with nonvalvular atrial and determine whether body mass index and estimated Glomerular Filtration Rate (eGFR) of Chronic kidney disease would give incremental information with CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-vasc scheme in predicting thromboembolic event in NVAf Saudi patients [10].

## MATERIALS AND METHODS

This is a non-randomized, retrospective study of patients above 18 years old diagnosed with nonvalvular AF within at King Faisal Specialist Hospital and Research Center (KFSH and RC), Riyadh. Physicians are used to assign diagnoses of nonvalvular AF between 01 Jan 2008 and 31 December 2013. Excluding patients with slight to severe rheumatic mitral valve disorder and valvular repair or replacement [11]. This study project was conducted in accordance with the ethical principles contained in the Declaration of Helsinki, the ICH Harmonized Tripartite Good Clinical Practice Guidelines (HTGCPG), the policies and guidelines of the research advisory committee of the KFSH and RC and the laws of Saudi Arabia. As this is a retrospective study and does not involve any direct contact with patients or their families and does not pose more than a minimal risk to patients, we consider the benefit to risk ratio to be favorable. Waiver of informed consent was obtained from the nature of the study.

We used administrative databases for information on patient age, gender, body mass index, previous ischemic stroke, diagnosed heart failure, known coronary heart disease, hypertension, diabetes and presence of vascular disease.

Baseline evaluation and investigative work up for all patients were used to derive their CHADS2 and CHA2DS2-vasc scores. A priori variables included the CHADS2 (congestive heart failure, hypertension, age>75, diabetes, previous stroke) and CHA2DS2-vasc (CHADS plus vascular disease, age 65-74 and female as gender category) clinical prediction rules were collected and considered for inclusion in the multivariate analyses for primary endpoints. The presence of each variable was given 1 point while a prior Cerebrovascular Accident (CVA), defined as ischemic stroke or Transient Ischemic Attack (TIA), conferred 2 points. When CHA2DS2-vasc was used 2 points were given for age>75 and point for age 65-74.

Kidney function was assessed by level of estimated glomerular filtration rate and were categorized as following. eGFR>60 ml/min, eGFR 30-59 ml/min, eGFR 16-29 ml/min eGFR<15 ml/min. And body mass index categorizes into underweight, normal, overweight and obese according to BMI level and weight status. A primary endpoint event is defined as the presence of any of the following: thromboembolic stroke, transient ischemic attack, Deep Venous Thrombosis (DVT) or systemic embolism during follow-up period of 730 days.

#### Statistical considerations

For this retrospective study, all the statistical analysis of data was done by using SPSS software (version 20.0.1 for Windows, SPSS Inc., Chicago, IL, USA). Descriptive statistics for the continuous variables and categorical variables and summarized as frequencies and percentages. Continuous variables compared by Student's t-test or ANOVA as appropriate, while categorical variables compared by Chi-square test. Univariate and multivariate logistic regression used to study the effect of the different risk factors on the primary outcomes of the study. The level of statistical significance is set at  $p<0.05$  [12].

### RESULTS AND DISCUSSION

Study identified of 541 patients with AF seen in our institution from 2008 to 2013 in database, 175 was NVAF. The proportion of males was 49.0% compared to 51% females. Patients suffering from congestive heart failure were 43%. Hypertension was 68.6% of the study subjects. A 29% of the study groups were older than 75 years old. Diabetes Mellitus (DM) was notice in 44% of the patients. There were 19.4% among NVAF had vascular disease (Table 1).

**Table 1 Demographic data for the patient involved in the study**

Patients characteristics	Number of patients	Percentage
Gender	85 Male	49.00%
	90 Female	51.00%
CHF	76	43.40%
HTN	120	68.60%
Age $\geq$ 75	51	29.10%
Age 65-74	53	30.30%
DM	77	44.00%
Prior stroke or TIA	23	13.14
Vascular disease	34	19.40%

There were 9.7% of study group having chronic kidney disease with eGFR<30 ml/min (Table 2).

**Table 2 Kidney function of study group assessed by level of estimated glomerular filtration rate**

Level of estimated glomerular filtration rate eGFR	Number of patients	Percentage
Not available	3	1.70%
Normal	109	62.30%
30-59	46	26.30%
<16-29	7	4.00%
<15	10	5.70%

BMI above 30 amounted to 50.9% of all cases, while normal BMI level amounted to only 17.1% (Table 3).

**Table 3 Distributions of Body Mass Index (BMI) involved in the study**

Wight status	BMI level	Number of patients	Percentage
	Not available	3	1.70%
Underweight	Below 18.5	2	1.10%
Normal	18.5-24.9	30	17.10%
Overweight	25.0-29.9	51	29.10%
Obese	30.0 and Above	89	50.90%

The number of patients that developed nonvalvular atrial fibrillation stratified by CHADS2 Score of 0, 1 and 2 or greater were 27, 34 and 114 correspondingly. While patients stratified by CHAD2DS2-vasc Score 0, 1 and 2 or greater 2 were 16, 17 and 142 respectively (Table 4).

**Table 4 CHADS2 and CHA2DS2-vasc score categories in the study sample**

CHADS2/CHA2DS2-vasc scheme	Score	Number of patients	Percentage
<b>CHADS2</b>	0	27	15.4% low Risk
	1	34	19.4% moderate risk
	2	50	28.6% high risk
	3	35	20.00%
	4	20	11.40%
	5	5	2.90%
	6	4	2.30%
<b>CHAD2DS2-vasc</b>	0	16	9.1% low risk
	1	17	9.7% moderate risk


	2	25	14.3% high risk
	3	33	18.90%
	4	32	18.30%
	5	23	13.10%
	6	15	8.60%
	7	9	5.10%
	8	3	1.70%
	9	2	1.10%

The characteristics of the cohort members who developed endpoints of interest: Thromboembolic stroke, transient ischemic attack, deep venous thrombosis and systemic embolism events during follow-up period of 730 days as primary outcome. A total of 26 (14.9%) developed thromboembolic event, seventeen of them had ischemic stroke (Table 5).

**Table 5 Thromboembolic stroke, Transient Ischemic Attack (TIA), Deep Venous Thrombosis (DVT) and systemic embolism events during follow-up period of 730 days**

Thrombus type	Number of patients	Percentage
Thromboembolic stroke	17	9.70%
TIA	3	1.70%
Systemic embolism	3	1.70%
DVT	1	0.60%
Stroke+systemic embolism	1	0.60%
Stroke+DVT	1	0.60%
Total of Thromboembolic event	26	14.90%


Age  $\geq$  75 years and vascular disease were significant factors for thromboembolic events. Patients who had previously attacked with stroke or TIA have a greater risk for thromboembolism (CI=1.572-4.161) (P value=0.000). Events rate of thromboembolic increased when CHADS2 score/CHAD2DS2-vasc Scores increased (Figures 1 and 2). Even with 12 patients from 26 patient who had thromboembolism were overweight and obese no statistically significant associations observed between BMI and thromboembolic risk (CI=0.733-1.995). Despite only 35% of study population is suffering from chronic kidney disease however level of estimated glomerular filtration rate assessing kidney function were significant factor for thromboembolic events in patients with nonvalvular atrial fibrillation (Table 6).



**Figure 1 Events rate of thromboembolic with CHADS2 score. Note: ■: No embolic events; ■: Embolic events**

**Table 6** Cox regression analysis of CHADS2, CHA2DS2-vasc scores components, Body Mass Index (BMI), chronic kidney disease by level of estimated Glomerular Filtration Rate (eGFR) and association with thromboembolic event.

Variable	Odds ratio	95% CI	P-value
Congestive heart failure	1.365	0.592-3.145	0.4649
Hypertension	2.862	0.936-8.752	0.0652
Age>75	3.532	1.501-8.312	0.0039
Diabetes mellitus	1.328	0.577-3.059	0.505
Prior stroke or transient ischemic attack	2.557	1.572-4.161	0.0002
CHADS2-Score	1.775	1.311-2.404	0.0002
Vascular Disease	3.255	1.320-8.029	0.0104
Age 65-74	1.027	0.416-2.535	0.9535
Gender	1.967	0.824-4.691	0.1274
CHAD2DS2-vasc Score	1.569	1.250-1.969	0.0001
BMI	1.209	0.733-1.995	0.4567
eGFR	1.704	1.112-2.610	0.0144



**Figure 2** Events rate of thromboembolic with C CHAD2DS2-vasc score. Note: ■: No embolic events; ■: Embolic events

Various risk stratification schemes are design to help prevent stroke and other thromboembolic events in atrial fibrillation patients. Most of the scores variables are considered risk for thromboembolism events even in absent of AF. One of most commonly use score is CHADS2 score and been validated in multiple populations. However due to the simplicity of CHADS2 score system has resulted inability identify low-risk group (CHADS2 score of 0-1) of AF patients [13].

So, to overcome the drawback of the CHADS2, the CHA2DS2-vasc scoring system was developed. Using all components of the CHADS2 system but with greater emphasis on age. As elderly patients carries near five-fold heightened risk of stroke in patients with non-valvular AF and includes two additional factors, female gender and vascular disease that found to be a predictor of thromboembolism in non-valvular AF. This finding is consistent with observations in our work showed CHADS2, CHA2DS2-vasc, elderly patient and vascular disease were significant factors for thromboembolic events in patient with NVAf [14].

Female gender is higher risk of stroke than male in AF patient as has been evident in the trials of stroke prevention in AF. However our retrospectively examined the risk of female patients with atrial fibrillation revealed similar thromboembolic risk in comparison with male patients when there is no additional risk factors. This finding is consistent with the proposed excluding the gender criterion in an analysis of the Japanese J-RHYTHM registry. Where no gender difference was found in patient groups stratified by CHA2DS2-vasc and CHA2DS2-VA scores. And current European and American AF guidelines recommend using the CHA2DS2-vasc score for guiding anticoagulation treatment decisions, but they differ with respect to their thresholds for men and women [15-20]. Congestive heart failure and atrial fibrillation frequently coexist and associated with increased risk of cardiovascular events. In our work no statistically significant associations were observed between congestive heart failure and TE in NVAF patients and events in our study were low [21].

Diabetes mellitus is also a significant independent risk factor for stroke. After adjusting for confounding factors, our study did not show statistically significant risk of thromboembolism in atrial fibrillation and Diabetes mellitus. Interestingly, the different levels of hba1c among patients with diabetes mellitus duration of  $\geq 10$  years were not associated with higher rates of thromboembolism which could explain our statistically finding [22-24]. History of hypertension shown to be risk factors for TE in AF. This finding was not confirmed in our study which could be attributed to the small sample size study and explain this lack of association. A prior stroke or transient ischemic attack is the strongest risk factors for stroke in AF patients are identified age and previous stroke as the most powerful predictors of stroke/embolism on a multivariate analysis in patients with NVAF. This finding is consistent with the observations in our work of patient who had previous stroke or TIA carry a greater risk for thromboembolism [25]. Obesity is cause of various negative cardiovascular outcomes and associated with a poor prognosis in patients with AF.

BMI is the most widely used marker of obesity, we retrospectively examined the risk. Our results are show that overweight and obesity were not associated with increased risk of TE. On other hand meta-analysis of nine studies including 49,364 patients noticed underweight (BMI $<18.5$  kg/m<sup>2</sup>) Asian patients with AF were at increased risk of embolic events. This finding could be attributed to lower BMI and unintentional weight loss may indicate disease progression in those patients. The Rocket AF study results showed that moderate renal failure is an independent risk factor for stroke among AF patients. In a retrospective analysis of large cohort of patients with AF showed low estimated glomerular filtration rate was associated with significantly increased risk of thromboembolism [26].

### CONCLUSION

The study is a single-center experience and generalization of the results may not be applicable. Patient compliance on anticoagulation was not well assessing because of the retrospective nature of the study and patients with incomplete follow up were excluded. There could be inter-observational variability in the assessment of the nonvalvular atrial fibrillation in the included patients. Study demonstrated CHADS2, CHA2DS2-vasc, CKD are predictor of TEs and should be included in risk stratification schemes among NVAF Saudi patients. And obese patient was not. So, keeping this association in consideration during thromboembolism risk assessment is recommended. Further study is needed to search for modifiable risk factors that are associated with increased risk thromboembolism in NVAF patient.

### DECLARATION

Declaration of competing interest. The authors have no conflict of interest to declare.

### REFERENCES

- [1] McBride R. Stroke prevention in atrial fibrillation study. Final results. *Circulation*. 84(2), 1991: 527-539.
- [2] Gage, Brian F, et al. Validation of clinical classification schemes for predicting stroke: Results from the National registry of atrial fibrillation. *J Am Med Assoc*. 285(22), 2001: 2864-2870.

- [3] Go AS, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? *J Am Med Assoc.* 290(20), 2003: 2685-2692.
- [4] Go AS, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. *Circulation.* 119(10), 2009: 1363-1369.
- [5] Olesen JB, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. *New Eng J Med.* 367(7), 2012: 625-635.
- [6] Piccini JP, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors in Atrial fibrillation) Study Cohorts. *Circulation.* 127(2), 2013: 224-232.
- [7] Go AS, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. *Ann Internal Med.* 131(12), 1999: 927-934.
- [8] Lip Gregory YH, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. *Chest.* 137(2), 2010: 63-272.
- [9] Coppens JW, et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. *Eur Heart J.* 34(3), 2013: 170-176.
- [10] Benjamin EJ, et al. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham heart study. *J Am Med Assoc.* 271(11), 1994: 840-844.
- [11] Hart RG, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials. *Stroke.* 30(6), 1999: 1223-1229.
- [12] Fang MC, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. *Circulation.* 112(12), 2005: 1687-1691.
- [13] Tomita HKO, et al. Validation of risk scoring system excluding female gender From CHA2DS2-VASc in Japanese patients With nonvalvular atrial fibrillation-subanalysis of the J-RHYTHM registry. *Circulation J.* 79(8), 2015: 1719-1726.
- [14] Kirchhof P, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation. *Eur Heart J.* 37, 2016: 2893-2962.
- [15] Overvad TF, et al. Treatment thresholds for stroke prevention in atrial fibrillation: Observations on the CHA2DS2-VASc score. *Eur Heart J Cardiovasc Pharmacother.* 3(1), 2017: 37-41.
- [16] January CT, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American college of Cardiology/American heart association task force on practice guidelines and the heart rhythm society. *J Am Coll Cardiol.* 64(21), 2014: 1-76.
- [17] Maisel WH, et al. Atrial fibrillation in heart failure: Epidemiology, pathophysiology and rationale for therapy. *Am J Card.* 91(6), 2003: 2-8.
- [18] Fangel MV, et al. Glycemic status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes mellitus: A Danish cohort study. *Circ Arrhythm Electrophysiol.* 12(5), 2019.
- [19] Ashburner JM, et al. Effect of diabetes and glycemic control on ischemic stroke risk in AF patients: ATRIA study. *J Am Coll Cardiol.* 67(3), 2016: 239-247.



- [20] Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study. *J Stroke Cerebrovasc Dis.* 5(3), 1995: 147-157.
- [21] Tsang TSM, et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: A longitudinal cohort study of 21 years. *Eur Heart J.* 29(18), 2008: 2227-2233.
- [22] Zhu W, et al. Relation of body mass index with adverse outcomes among patients with atrial fibrillation: A meta-analysis and systematic review. *J Am Heart Assoc.* 5(9), 2016: 4006.
- [23] Zamora E, et al. Weight loss in obese patients with heart failure. *J Am Heart Assoc.* 5(3), 2016: e002468.
- [24] Marinigh R, et al. Severe renal impairment and stroke prevention in atrial fibrillation: Implications for thromboprophylaxis and bleeding risk. *J Am Coll Cardiol.* 57(12), 2011: 1339-1348.
- [25] Roldan V, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? *Thromb Haemost.* 109(05), 2013: 956-960.
- [26] Kornej J, et al. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc and R2CHADS2) and the risk of thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig heart center AF ablation registry. *Circ Arrhythm Electrophysiol.* 6(5), 2013: 868-874.

